3 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $4M | -$161M | 0.0% | -4722.1% | -$132M | $3M | $32M |
| 2024 | $1M | -$88M | 0.0% | -10067.3% | -$79M | $0 | $257M |
| 2023 | $204000 | -$49M | 0.0% | -27180.9% | — | — | $8M |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $1M | -$60M | 0.0% | -6130.1% | -$57M | $3M | $34M |
| Dec '25 | $2M | -$41M | 0.0% | -2097.3% | -$36M | $3M | $32M |
| Sep '25 | $2M | -$44M | 0.0% | -3069.0% | -$39M | $3M | $45M |
| Jun '25 | $0 | -$41M | — | — | -$28M | — | $15M |
| Mar '25 | $52000 | -$34M | 0.0% | -81161.5% | -$29M | — | $41M |
| Dec '24 | $456000 | -$32M | 0.0% | -8344.1% | -$21M | $0 | $257M |
| Sep '24 | $43000 | -$20M | 0.0% | -65802.3% | -$16M | — | $43M |
| Jun '24 | $111000 | -$19M | 0.0% | -23291.0% | -$16M | — | $25M |
| Mar '24 | $529000 | -$17M | 0.0% | -4247.4% | -$26M | — | $77M |
| Dec '23 | $1000 | -$17M | 0.0% | -1935500.0% | — | — | $8M |
| Sep '23 | $9000 | -$12M | 0.0% | -156033.3% | — | — | — |
| Jun '23 | $0 | -$12M | — | — | — | — | — |
| Mar '23 | $194000 | -$9M | 0.0% | -5010.8% | — | — | — |
How the market has priced CGON against its own fundamentals since 2024-01 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 2 years, Cg Oncology, Inc.'s revenue has grown 345.0% per year. These are computed facts, not advice.
As of FY2025, Cg Oncology, Inc. reported $3M of total debt against $32M of cash.
In FY2025, gross margin was —, operating margin -4722.1%, and net margin -3985.1%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.